<< Exhibitor
<< Press release
The 24th China International In Vitro Diagnostics by CACLP will officially take place 19-21 March 2027 at the Nanjing International Expo Center in Nanjing, Jiangsu Province, China.
The 23rd China International In Vitro Diagnostics by CACLP was successfully held from 21-23 March 2026 in Xiamen, marking another milestone in the event’s continued expansion across China, Southeast Asia and the global market.
In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:
As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.
Amid the deepening implementation of the Healthy China 2030 strategy and the rapid convergence of a new global biotechnology revolution, in vitro diagnostics (IVD) has become more critical than ever.
The 11th China Experimental Medicine Conference, themed “Innovation Shaping the Future,” will be held from 21-22 March, 2026, in Xiamen.
As a vital link between innovation and clinical application, IVD distribution enterprises play an indispensable role in ensuring the efficient flow of diagnostic products and services.
Driven by rapid advances in healthcare technology, the IVD industry is entering a new era of innovation and growth. Enlightening Lab Med —— The 9th IVD Youth Entrepreneur Forum will take place on 21 March 2026 at the Xiamen International Expo Center.
As the global in vitro diagnostics (IVD) industry advances toward greater technological sophistication, intelligent automation, and broader clinical applications, the focus of innovation is shifting upstream. Beyond the development of cutting-edge instruments and assays, increasing attention is being placed on the foundational elements that enable performance and reliability—namely critical raw materials, core components, and robust standards systems. Breakthroughs in advanced materials, precision-engineered components, and cross-disciplinary integration are becoming central drivers of sustainable industry growth.
With less than one month remaining before its official opening, the 23rd China International In Vitro Diagnostics by CACLP, together with a series of academic conferences, industry forums, and business meetings, has entered its final countdown stage.
<< Industry news
It is a product of URIT. On the basis of the original urine routine analysis workflow, US-3000 series has added urine-specific protein module and urine biochemistry detection module to realize one-stop detection of urine physics, dry chemistry, formed element, specific protein, and biochemical quantification. On the basis of all-in-one machine, US-1680 series adds online functions to meet the needs of different markets.
Teal Health, creators of the Teal WandTM, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A funding to meet accelerating consumer demand and expand access ahead of broad insurance coverage beginning in January 2027.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC).
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Urine ID/AST Panel. The Urine ID/AST Panel is the company’s second assay to receive the designation, following the Pneumonia ID/AST Panel. It reflects Pattern’s continued focus on expansion of a menu of rapid, direct-from-specimen assays.
Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The companies are engaged in several projects to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing.
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel and BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel Mini have been CE-marked under the IVDR*. The certification includes conformity assessment for near-patient testing, enabling its use outside traditional laboratories, directly at the point of care. These multiplex PCR** tests can simultaneously detect the most common pathogens responsible for respiratory and sore throat infections, within a timeframe aligned with a typical patient visit.
Produced by Mejer, it is the first instrument in China that uses S-M staining method combined with AI technology to automatically identify urine formed elements.
Amoy Diagnostics Co., Ltd. (“AmoyDx,” SZSE: 300685) today announced that its AmoyDx® HRD Complete Panel has received certification under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR) by TÜV SÜD Product Service GmbH for use as a companion diagnostic to aid in identifying patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations ( germline and /or somatic) who may be eligible for treatment with olaparib monotherapy who have progressed following prior therapy that included a novel hormonal agent.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.
<< Video showcase
Talk with Prof. Leslie Lam at CACLP 2026
Talk with Prof. Vittorio Sambri at CACLP 2026
Talk with Prof. Sergio Bernardini at CACLP 2026
Talk with Prof. Rajiv Erasmus at CACLP 2026
Talk with Prof. Aldo Tomasi at CACLP 2026
Talk with Yinan Tang at CACLP 2026
Talk with Shaoting Zhang at CACLP 2026
Talk with Huai Chen at CACLP 2026
Talk with CHIA Wai Kian at CACLP 2026
Talk with Rahul AGARWAL at CACLP 2026
Talk with Jag Grewal at CACLP 2026
CACLP 2026 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 13th China IVD Industry Development Conference & The 11th China Experimental Medicine Conference
CACLP International Night 2026
The 1st Global IVD Innovation Summit
Go Global: China IVD International Forum 2026
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
<< Download centre
CACLP 2026 Post-show Report
CACLP 2026 Floor Plan
CACLP 2026 Full Schedule
CACLP 2026 Exhibitor Manual
CACLP 2025 Post-show Report
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
